AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1361797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 54
Study 1361797 — intervention group
Group type: COMPARATOR
Intervention: Neomycin sulphate nasal ointment
Number of subjects: 54
Study 1361797 — intervention group
Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 54
Study 29097103 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of peanut
Number of subjects: 0
Study 26556234 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM intervention (five 1‐h instructional sessions)
Number of subjects: 47
Study 26556234 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 47
Study 26556234 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM intervention
Number of subjects: 47
Study 24253788 — intervention group
Group type: EXPERIMENTAL
Intervention: Actifuse combined with 5 mL of bone marrow aspirate (n = 26)
Number of subjects: 52
Study 24253788 — intervention group
Group type: COMPARATOR
Intervention: rhBMP-2 (4.2 mg, n = 26)
Number of subjects: 52
Study 22089917 — intervention group
Group type: EXPERIMENTAL
Intervention: LISS (Less Invasive Stabilization System)
Number of subjects: 64
Study 22089917 — intervention group
Group type: COMPARATOR
Intervention: PFNA (Proximal Femoral Nail Anti-rotation)
Number of subjects: 64
Study 20823643 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg per day)
Number of subjects: 85
Study 20823643 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (8 mg per day)
Number of subjects: 85
Study 20823643 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg per day) in obese subjects
Number of subjects: 85
Study 18226614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (15 sessions over three months)
Number of subjects: 201
Study 18226614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 201
Study 18226614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 201
Study 15691639 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFU (5FU 3 g/m2 intravenously, 24 h infusion, weekly for 6 weeks)
Number of subjects: 58
Study 15691639 — intervention group
Group type: COMPARATOR
Intervention: 5FU+FA+CDDP (5FU 2.0 g/m2 i.v. with folinic acid 500 mg/m2, 2 h-infusion, weekly for 6 weeks + cisplatin 50 mg/m2, once every two weeks for 6 weeks)
Number of subjects: 58
Study 16285495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with perioral dermatitis (PD)
Number of subjects: 40
Study 10376776 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (70 mg, once per week)
Number of subjects: 43
Study 10376776 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (3030 RE, once per week)
Number of subjects: 43
Study 10376776 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and Vitamin A (70 mg Zn and 3030 RE vitamin A, once per week)
Number of subjects: 43
Study 10376776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8687262 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 849
Study 8687262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 1800107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision condition
Number of subjects: 6
Study 1800107 — intervention group
Group type: COMPARATOR
Intervention: No-vision condition
Number of subjects: 6
Study 6398981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in PUFA
Number of subjects: 0
Study 6398981 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 30515970 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab (TNF inhibitor)
Number of subjects: 50
Study 30515970 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab (IL-12/23 inhibitor)
Number of subjects: 50
Study 30342645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection (7.5% ropivacaine, 10 mL total, 5 mL each into both uterosacral ligaments)
Number of subjects: 40
Study 30342645 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (10 mL total, 5 mL each into both uterosacral ligaments)
Number of subjects: 40
Study 26275768 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed home-based walking intervention (12 weeks of moderate intensity walking)
Number of subjects: 50
Study 26275768 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study 24804802 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored instruction (individual)
Number of subjects: 136
Study 24804802 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-tailored instruction (TEAM)
Number of subjects: 136
Study 24804802 — intervention group
Group type: COMPARATOR
Intervention: Standardized brochures (control)
Number of subjects: 136
Study 21244523 — intervention group
Group type: EXPERIMENTAL
Intervention: C + 250 FTU
Number of subjects: 32
Study 21244523 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study 20155829 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 150
Study 20155829 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 150
Study 20155829 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 150
Study 20155829 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study 15988475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 0
Study 15988475 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 12551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate induction of labor (n=124)
Number of subjects: 249
Study 12551783 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (n=125)
Number of subjects: 249
Study 10710805 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose and 0.075% lidocaine in bacteriostatic water (active solution)
Number of subjects: 38
Study 10710805 — intervention group
Group type: COMPARATOR
Intervention: Control solution absent 10% dextrose
Number of subjects: 38
Study 10710805 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose
Number of subjects: 38
Study 26630718 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Cross Canker Sore Medication
Number of subjects: 21
Study 26630718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Strength Anbesol
Number of subjects: 21
Study 26630718 — intervention group
Group type: EXPERIMENTAL
Intervention: Orajel Mouth Aid
Number of subjects: 21
Study 1490488 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxicam (20 mg single dose)
Number of subjects: 25
Study 1490488 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxicam (20 mg/day for 30 consecutive days)
Number of subjects: 25
Study 1490488 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg single dose)
Number of subjects: 25
Study 1490488 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg/day for 30 consecutive days)
Number of subjects: 25
Study 3858894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg DST
Number of subjects: 83
Study 3858894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg DST
Number of subjects: 83
Study 3858894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1-mg and 2-mg DST with 119 semi-consecutive admissions
Number of subjects: 83
Study 3858894 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 83
Study 30474431 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker sole shoes
Number of subjects: 20
Study 30474431 — intervention group
Group type: COMPARATOR
Intervention: Flat-bottomed shoes
Number of subjects: 20
Study 30921979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVLI) 2 mg/minute for 4 hours
Number of subjects: 111
Study 30921979 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution 0.9% (Control)
Number of subjects: 111
Study 28589771 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 13
Study 25758436 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) used before, during and after HIFU treatment (Group A)
Number of subjects: 33
Study 25758436 — intervention group
Group type: COMPARATOR
Intervention: No CEUS administered (Group B)
Number of subjects: 33
Study 24061557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (L-CHO) diet
Number of subjects: 47
Study 24061557 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (H-CHO) diet
Number of subjects: 47
Study 21051458 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 41
Study 21051458 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (rate control)
Number of subjects: 41
Study 19337241 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 19337241 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 60
Study 16455834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 18
Study 16455834 — intervention group
Group type: COMPARATOR
Intervention: Flutter(R)
Number of subjects: 18
Study 16455834 — intervention group
Group type: COMPARATOR
Intervention: Percussion
Number of subjects: 18
Study 16455834 — intervention group
Group type: COMPARATOR
Intervention: Acapella(R)
Number of subjects: 18
Study 16455834 — intervention group
Group type: COMPARATOR
Intervention: Positive expiratory pressure
Number of subjects: 18
Study 15190528 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-135 5 mg, twice daily
Number of subjects: 511
Study 15190528 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-135 25 mg, twice daily
Number of subjects: 511
Study 15190528 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-135 50 mg, twice daily
Number of subjects: 511
Study 15190528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 12587476 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy only, delivered with megavoltage linear accelerator, combined with intracavitary brachytherapy in some patients, total tumor dose range 55-75 Gy
Number of subjects: 34
Study 9572815 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (30 g creatine + 30 g dextrose per day)
Number of subjects: 8
Study 9572815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 g dextrose per day)
Number of subjects: 8
Study 8589479 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2x10(6) IU/g) applied thrice daily for 5 consecutive days
Number of subjects: 60
Study 8589479 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study 2751920 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 0
Study 775616 — intervention group
Group type: EXPERIMENTAL
Intervention: Colo-rectal operations
Number of subjects: 56
Study 775616 — intervention group
Group type: EXPERIMENTAL
Intervention: All operations
Number of subjects: 56
Study 775616 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation wounds
Number of subjects: 56
Study 31291984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture with hominis placenta extract (PLC), administered twice a week for a total of 18 sessions over 9 weeks.
Number of subjects: 128
Study 31291984 — intervention group
Group type: COMPARATOR
Intervention: Injections of normal saline, administered at the same acupoints during the same period as PLC.
Number of subjects: 128
Study 28506917 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial antitachycardia pacing plus managed ventricular pacing (DDDRP+MVP)
Number of subjects: 1166
Study 28506917 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber pacing (Control DDDR)
Number of subjects: 1166
Study 28506917 — intervention group
Group type: COMPARATOR
Intervention: Managed ventricular pacing (MVP)
Number of subjects: 1166
Study 25000447 — intervention group
Group type: EXPERIMENTAL
Intervention: Term-SGA
Number of subjects: 4130
Study 25000447 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm-SGA
Number of subjects: 4130
Study 25000447 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm-AGA
Number of subjects: 4130
Study 23432520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate alcohol consumption
Number of subjects: 41
Study 23432520 — intervention group
Group type: COMPARATOR
Intervention: Light alcohol consumption
Number of subjects: 41
Study 23432520 — intervention group
Group type: COMPARATOR
Intervention: Heavy alcohol consumption
Number of subjects: 41
Study 23432520 — intervention group
Group type: COMPARATOR
Intervention: Negative mood
Number of subjects: 41
Study 20735800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-1-12 months vaccination schedule
Number of subjects: 399
Study 20735800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-1-6 months vaccination schedule
Number of subjects: 399
Study 20735800 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 399
Study 19221299 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE D/I polymorphism (DD and DI genotypes)
Number of subjects: 25000
Study 19221299 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE D/I polymorphism (II genotype)
Number of subjects: 25000
Study 19221299 — intervention group
Group type: COMPARATOR
Intervention: ACE D/I polymorphism
Number of subjects: 25000
Study 17014060 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Number of subjects: 21
Study 17014060 — intervention group
Group type: COMPARATOR
Intervention: Non-protease inhibitors (non-PIs)
Number of subjects: 21
Study 15341255 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day) + Diane35 (for the first two months)
Number of subjects: 30
Study 15341255 — intervention group
Group type: COMPARATOR
Intervention: Metformin (850 mg twice a day)
Number of subjects: 30
Study 11703472 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 273
Study 9149164 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma) levels in nasal polyps
Number of subjects: 27
Study 9149164 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous polypectomy surgery
Number of subjects: 27
Study 9149164 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpopulations based on IFN‐gamma levels
Number of subjects: 27
Study 7967853 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered symptom severity scale
Number of subjects: 74
Study 7967853 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered functional status scale
Number of subjects: 74
Study 7967853 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered activities of daily living scale
Number of subjects: 74
Study 7967853 — intervention group
Group type: COMPARATOR
Intervention: Traditional measures of strength and sensibility
Number of subjects: 74
Study 3410484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (60 mg)
Number of subjects: 0
Study 3410484 — intervention group
Group type: COMPARATOR
Intervention: Lactose (60 mg)
Number of subjects: 0
Study 31401126 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Pump System (APS)
Number of subjects: 42
Study 31401126 — intervention group
Group type: COMPARATOR
Intervention: Gravity Flow System (GFS)
Number of subjects: 42
Study 29871197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pyruvate nasal spray
Number of subjects: 53
Study 24317176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 736
Study 24317176 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 250 mg
Number of subjects: 736
Study 22900930 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus thoracic epidural anesthesia (GA + TEA)
Number of subjects: 540
Study 22900930 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (GA)
Number of subjects: 540
Study 20817638 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 10
Study 20817638 — intervention group
Group type: EXPERIMENTAL
Intervention: Jazz music
Number of subjects: 10
Study 20817638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-hop music
Number of subjects: 10
Study 20817638 — intervention group
Group type: EXPERIMENTAL
Intervention: Jamaican music
Number of subjects: 10
Study 17646506 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL saline (distention)
Number of subjects: 203
Study 17646506 — intervention group
Group type: COMPARATOR
Intervention: 2 mL (nondistention)
Number of subjects: 203
Study 16238116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol) 40 mg once daily at bedtime for 6 weeks
Number of subjects: 35
Study 16238116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (Sortis) 10 mg once daily at bedtime for 6 weeks
Number of subjects: 35
Study 16238116 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically healthy subjects)
Number of subjects: 35
Study 12396958 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment with amoxicillin, clarithromycin, and omeprazole for 7 days
Number of subjects: 49
Study 12396958 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 7 days
Number of subjects: 49
Study 10685268 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 40
Study 10685268 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 7531394 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 200 micrograms per square meter per day subcutaneously until ANC > 1,500/mm³ (group B)
Number of subjects: 50
Study 7531394 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF prophylactically used in high-dose cytosine arabinoside regimens (group C)
Number of subjects: 50
Study 7531394 — intervention group
Group type: COMPARATOR
Intervention: No G‐CSF used (group A)
Number of subjects: 50
Study 2360871 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60 min per day, 3.5 days per week, targeting 75‐80% of maximum aerobic working capacity)
Number of subjects: 78
Study 2360871 — intervention group
Group type: COMPARATOR
Intervention: Organized walking (control group, 60 min per day, 4.1 days per week)
Number of subjects: 78
Study 6994866 — intervention group
Group type: COMPARATOR
Intervention: Imidazole carboxamide (DTIC) alone
Number of subjects: 49
Study 6994866 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus Corynebacterium parvum
Number of subjects: 49
Study 31599476 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg or 300 mg
Number of subjects: 3010
Study 31599476 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg (active comparator)
Number of subjects: 3010
Study 31599476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3010
Study 31577772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavioral Therapy (REBT)
Number of subjects: 116
Study 31577772 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 116
Study 27836862 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m2) for 5 days prior to EOX chemotherapy (E: 50 mg/m2, O: 130 mg/m2, X: 625 mg/m2 twice daily for 21 days)
Number of subjects: 12
Study 27836862 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m2) for 3 days prior to EOX chemotherapy
Number of subjects: 12
Study 25801556 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus ascorbic acid (2 g every 12 h)
Number of subjects: 28
Study 25801556 — intervention group
Group type: COMPARATOR
Intervention: Colistin alone
Number of subjects: 28
Study 25801556 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus ascorbic acid
Number of subjects: 28
Study 23652808 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 610
Study 21865979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (5 mL daily)
Number of subjects: 132
Study 21865979 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SO) supplementation (5 mL daily)
Number of subjects: 132
Study 21865979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 132
Study 19625243 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide XL, 10 mg orally daily (G group)
Number of subjects: 77
Study 19625243 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide XL, 10 mg orally daily, plus insulin glargine, 10 U daily (G+G group)
Number of subjects: 77
Study 19625243 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (G and G+G)
Number of subjects: 77
Study 17346444 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% PLA2 inhibitor-containing cream
Number of subjects: 11
Study 17346444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16980850 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Number of subjects: 4296
Study 16980850 — intervention group
Group type: EXPERIMENTAL
Intervention: Scar ranking
Number of subjects: 4296
Study 14610134 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for spontaneous intracranial hypotension (exact treatment not specified)
Number of subjects: 13
Study 14610134 — intervention group
Group type: COMPARATOR
Intervention: Control group of sex- and age-matched neurology inpatients with normal CSF pressure
Number of subjects: 13
Study 10474118 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (daily s.c. injections at a weekly dose of 8.2 mg/m(2) for 1.9-7.5 years)
Number of subjects: 49
Study 10474118 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 49
Study 9102589 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 1 ml (group A)
Number of subjects: 100
Study 9102589 — intervention group
Group type: COMPARATOR
Intervention: 1% bupivacaine 0.5 ml (group B)
Number of subjects: 100
Study 1654739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (OB)
Number of subjects: 20
Study 1654739 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran (WB)
Number of subjects: 20
Study 1654739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20